Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study

Cristiano S Moura, Michal Abrahamowicz, Marie-Eve Beauchamp, Diane Lacaille, Yishu Wang, Gilles Boire, Paul R Fortin, Louis Bessette, Claire Bombardier, Jessica Widdifield, John G Hanly, Debbie Feldman, Walter Maksymowych, Christine Peschken, Cheryl Barnabe, Steve Edworthy, Sasha Bernatsky, CAN-AIM, Cristiano S Moura, Michal Abrahamowicz, Marie-Eve Beauchamp, Diane Lacaille, Yishu Wang, Gilles Boire, Paul R Fortin, Louis Bessette, Claire Bombardier, Jessica Widdifield, John G Hanly, Debbie Feldman, Walter Maksymowych, Christine Peschken, Cheryl Barnabe, Steve Edworthy, Sasha Bernatsky, CAN-AIM

Abstract

Introduction: Use of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) may prevent joint damage and potentially reduce joint replacement surgeries. We assessed the association between RA drug use and joint replacement in Quebec, Canada.

Methods: A cohort of new-onset RA patients was identified from Quebec's physician billing and hospitalization databases from 2002-2011. The outcome was defined using procedure codes submitted by orthopedic surgeons. Medication use was obtained from pharmacy databases. We used alternative Cox regression models with time-dependent variables measuring the cumulative effects of past use during different time windows (one model focussing on the first year after cohort entry) for methotrexate (MTX), and other DMARDs. Models were adjusted for baseline sociodemographics, co-morbidity and prior health service use, time-dependent cumulative use of other drugs (anti-tumor necrosis factor [anti-TNF] agents, other biologics, cyclooxygenase-2 inhibitors [COXIBs], nonselective nonsteroidal antiinflammatory drugs [NSAIDs], and systemic steroids), and markers of disease severity.

Results: During follow-up, 608 joint replacements occurred among 11,333 patients (median follow-up: 4.6 years). The best-fitting model relied on the cumulative early use (within the first year after cohort entry) of MTX and of other DMARDs, with an interaction between MTX and other DMARDs. In this model, greater exposure within the first year, to either MTX (adjusted hazard ratio, HR = 0.95 per 1 month, 95% confidence interval, 95% CI 0.93-0.97) or other DMARDs (HR = 0.97, 95% CI 0.95-0.99) was associated with longer time to joint replacement.

Conclusions: Our results suggest that longer exposure to either methotrexate (MTX) or other DMARDs within the first year after RA diagnosis is associated with longer time to joint replacement surgery.

Figures

Fig. 1
Fig. 1
Kaplan-Meier estimates of time to joint replacement surgery. Groups of drug exposure were based on treatment(s) received during the first year after the cohort entry: 1) users of methotrexate (MTX) only (Metho_only); 2) users of other disease-modifying anti-rheumatic drugs (DMARD) only (DMARDs_only); 3) users of both MTX and DMARDs (Metho_DMARDs); and 4) patients not prescribed either MTX or any other DMARD during the first year of follow up (None)

References

    1. Widdifield J, Paterson JM, Bernatsky S, Tu K, Tomlinson G, Kuriya B, et al. The epidemiology of rheumatoid arthritis (RA) in Ontario. Canada Arthritis Rheum. 2013;66:786–93. doi: 10.1002/art.38306.
    1. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–82. doi: 10.1016/S0140-6736(08)61000-4.
    1. van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2013;73:861–70. doi: 10.1136/annrheumdis-2012-203130.
    1. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum. 2003;48:1771–4. doi: 10.1002/art.11156.
    1. James D, Young A, Kulinskaya E, Knight E, Thompson W, Ollier W, et al. Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years. Rheumatology (Oxford) 2004;43:369–76. doi: 10.1093/rheumatology/keh059.
    1. Jamsen E, Virta LJ, Hakala M, Kauppi MJ, Malmivaara A, Lehto MU. The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of anti-rheumatic therapy: a nationwide register-based study from 1995 through 2010. Acta Orthop. 2013;84:331–7. doi: 10.3109/17453674.2013.810519.
    1. Widdifield J, Bernatsky S, Paterson JM, Tu K, Ng R, Thorne JC, et al. Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis: a validation study using the medical records of rheumatologists. Arthritis Care Res (Hoboken) 2013;65:1582–91.
    1. Abrahamowicz M, Tamblyn R. Drug utilization patterns. In: Armitage P, Colton T, editors. Encyclopedia of Biostatistics. 2. Chichester: John Wiley & Sons; 2005. pp. 1533–53.
    1. Abrahamowicz M, Bartlett G, Tamblyn R, du Berger R. Modeling cumulative dose and exposure duration provided insights regarding the associations between benzodiazepines and injuries. J Clin Epidemiol. 2006;59:393–403. doi: 10.1016/j.jclinepi.2005.01.021.
    1. Abrahamowicz M, Beauchamp ME, Sylvestre MP. Comparison of alternative models for linking drug exposure with adverse effects. Stat Med. 2012;31:1014–30. doi: 10.1002/sim.4343.
    1. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1973;19:716–23. doi: 10.1109/TAC.1974.1100705.
    1. Sylvestre MP, Abrahamowicz M. Flexible modeling of the cumulative effects of time-dependent exposures on the hazard. Stat Med. 2009;28:3437–53. doi: 10.1002/sim.3701.
    1. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum. 2006;55:864–72. doi: 10.1002/art.22353.
    1. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50:2072–81. doi: 10.1002/art.20351.
    1. Kyburz D, Gabay C, Michel BA, Finckh A. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology (Oxford) 2011;50:1106–10. doi: 10.1093/rheumatology/keq424.
    1. Verstappen SM, Hoes JN, Ter Borg EJ, Bijlsma JW, Blaauw AA, van Albada-Kuipers GA, et al. Joint surgery in the Utrecht Rheumatoid Arthritis Cohort: the effect of treatment strategy. Ann Rheum Dis. 2006;65:1506–11. doi: 10.1136/ard.2005.049957.
    1. Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum. 2003;48:46–53. doi: 10.1002/art.10727.
    1. Wiles NJ, Lunt M, Barrett EM, Bukhari M, Silman AJ, Symmons DP, et al. Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum. 2001;44:1033–42. doi: 10.1002/1529-0131(200105)44:5<1033::AID-ANR182>;2-G.
    1. Louie GH, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983–2007. Ann Rheum Dis. 2007;69:868–71. doi: 10.1136/ard.2009.112474.
    1. Weiss RJ, Ehlin A, Montgomery SM, Wick MC, Stark A, Wretenberg P. Decrease of RA-related orthopaedic surgery of the upper limbs between 1998 and 2004: data from 54,579 Swedish RA inpatients. Rheumatology (Oxford) 2008;47:491–4. doi: 10.1093/rheumatology/ken009.
    1. Sokka T, Kautiainen H, Hannonen P. Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved long-term outcomes of rheumatoid arthritis. Ann Rheum Dis. 2007;66:341–4. doi: 10.1136/ard.2006.057067.
    1. Momohara S, Tanaka S, Nakamura H, Mibe J, Iwamoto T, Ikari K, et al. Recent trends in orthopedic surgery performed in Japan for rheumatoid arthritis. Mod Rheumatol. 2011;21:337–42. doi: 10.3109/s10165-011-0426-7.
    1. Ting G, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Young M, et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther. 2008;10:R95. doi: 10.1186/ar2482.
    1. Wolfe F, Michaud K, Simon T. Can severity be predicted by treatment variables in rheumatoid arthritis administrative data bases? J Rheumatol. 2006;33:1952–6.
    1. Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010;69:1086–91. doi: 10.1136/ard.2009.120626.
    1. Laudicella M, Siciliani L, Cookson R. Waiting times and socioeconomic status: evidence from England. Soc Sci Med. 2010;74:1331–41. doi: 10.1016/j.socscimed.2011.12.049.
    1. Hawker GA, Wright JG, Glazier RH, Coyte PC, Harvey B, Williams JI, et al. The effect of education and income on need and willingness to undergo total joint arthroplasty. Arthritis Rheum. 2002;46:3331–9. doi: 10.1002/art.10682.
    1. Schmajuk G, Solomon DH, Yazdany J. Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review. Arthritis Care Res (Hoboken) 2013;65:1927–35. doi: 10.1002/acr.22084.
    1. Jonsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ. 2008;8:S61–86. doi: 10.1007/s10198-007-0089-7.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe